cardiovascular-agents and plerixafor

Despite significant advances in the detection, prevention and treatment of congestive heart failure, it remains a leading cause of morbidity and mortality. Recent research has revealed the potential role of stem and progenitor cells in repairing and regenerating damaged myocardium. A number of pharmacological agents that mobilize these cells, including granulocyte-colony stimulating factor, statins and AMD-3100, are currently under investigation. This review summarizes the rationale behind using these agents, as well as describing the preclinical and clinical data supporting their efficacy.

Topics: Animals; Benzylamines; Cardiovascular Agents; Cyclams; Endothelial Cells; Heart Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Receptors, CXCR4; Receptors, Granulocyte Colony-Stimulating Factor; Regeneration